New CAR-T therapy aims to tackle tough lymphoma

NCT ID NCT07506668

Not yet recruiting Disease control Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy made from donor cells (allogeneic CAR-T) that targets two proteins on cancer cells. The main goals are to see if it is safe and if it can shrink tumors. Up to 19 adults will receive a single infusion of these cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RN1701 (a bispecific CD19/CD20-targeted allogeneic CAR-T cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for patients with B-cell lymphoma that has not responded to other therapies.
What could go wrong: This is a very early, small study (Phase 1/2) with only 10-19 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome (CRS) and other toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma follicular lymphoma large B-cell lymphoma mantle cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B-CELL LYMPHOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.